Literature DB >> 21676661

Investigation of competitive binding of ibuprofen and salicylic acid with serum albumin by affinity capillary electrophoresis.

Zhu-Mei Li1, Chuan-Wan Wei, Yintang Zhang, Di-Shan Wang, You-Nian Liu.   

Abstract

Ibuprofen and salicylic acid, two typical non-steroidal anti-inflammatory drugs, are used commonly as analgesic drug in clinical medicine and sometimes are co-administered. When the drugs are co-administered, the drug-drug interactions may occur, and can lead to alter the safety and efficacy of drugs, resulting in variations in drug response of the co-administered drugs. Affinity capillary electrophoresis (ACE) was employed to investigate the competitive binding of ibuprofen and salicylic acid on serum albumin. Mobility ratio, derivatives from mobility shift method, was used to deduce the binding constant (K(b)). The binding constants of ibuprofen with HSA are 2.97×10⁶ M⁻¹ and 7.07×10⁴ M⁻¹, respectively; while for salicylic acid, the binding constant is 5.99×10⁴ M⁻¹. The competitive binding of the two drugs was investigated by addition of excessive ibuprofen into the solutions containing constant concentrations of salicylic acid and serum albumin. The results confirmed that ibuprofen and salicylic acid have different high-affinity binding site, but share some low-affinity binding sites on the serum albumin; and ibuprofen is able to partially replace salicylic acid from the preformed binary complexes of serum albumin and salicylic acid.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21676661     DOI: 10.1016/j.jchromb.2011.05.020

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  1 in total

Review 1.  Clinical and pharmaceutical applications of affinity ligands in capillary electrophoresis: A review.

Authors:  Chenhua Zhang; Ashley G Woolfork; Kyungah Suh; Susan Ovbude; Cong Bi; Marawan Elzoeiry; David S Hage
Journal:  J Pharm Biomed Anal       Date:  2019-09-12       Impact factor: 3.935

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.